OPPI names Suresh Pattathil as new President, Health News, ET HealthWorld

OPPI names Suresh Pattathil as new President

Mumbai: The Organisation of Pharmaceutical Producers of India (OPPI), which represents the research-based pharmaceutical companies, has elected Suresh Pattathil as its next President. The term is for a period of two years and is effective from September 26, 2022. Pattathil will succeed S Sridhar, MD, Pfizer India Limited, who has been with the association since 2021.

Suresh Pattathil is the Managing Director and General Manager, Allergan, an AbbVie Company. He is responsible for commercial operations in India and South Asia markets. With more than 30 years of experience in the pharmaceutical industry. He has held several senior management positions in companies such as Pfizer, Schering Plough, MSD and Ferring.

Speaking on his appointment, Pattathil shared, “I am honoured to take this responsibility at this critical juncture for healthcare in the country. I look forward to making a difference to patients and the industry as OPPI works with the government to enable healthcare access. I thank the members of OPPI’s Executive Committee who selected me for this role.”

Commenting on the development, Vivek Sehgal, Director General, OPPI, said, “I welcome Suresh on-board and am confident that with his expertise, we will be able to achieve many more milestones and remain committed to enhancing OPPI’s leadership in bringing innovative drugs and new therapies for unmet medical needs. He has always been a strong voice for healthcare transformation in the country and under his able leadership we will continue to put in efforts to optimize patient outcomes by creating an environment conducive to innovation and growth as well as continue to engage deeply with the government stakeholders.”

Most recently Pattathil was the Chief Executive Officer for Ferring Pharmaceuticals India with responsibility for commercial operations, research & development centre and setting up a pilot plant and manufacturing facility in Hyderabad. He has a broad experience in both specialty as well as mass therapeutic areas and in launching global products successfully in India.

Source link